• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Switzerland·Healthcare·AEVS.SW
Share

Aevis Victoria SA Stocks

CHF 12.8Last Updated 27.08.2026

Issuer Rating

4/7
Performance

Average

Risk

Moderate

Recommendation

Hold

Market Cap

CHF 1.35B

CHF 12.8
Key Takeaways

Risk factor

Significant default risk

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Aevis Victoria SA is a Swiss holding company with diversified interests spanning the healthcare, hospitality, lifestyle, and infrastructure sectors. Its operational structure is divided into key segments: Hospitals, Hospitality, Telemedicine, and Real Estate. The group manages an extensive portfolio, which includes 22 hospitals providing 1,496 beds, and oversees 941 rooms within its real estate holdings, representing a total rentable area of 188,109 square meters. Beyond its core hospital services, Aevis Victoria offers telemedicine, ambulance transport, and day clinic facilities. Its broad range of business ventures further encompasses patient hotels, "better aging" programs, radiology institutes, pharmacies, ophthalmology clinics, property management, stem cell applications, cosmetic services, and publishing, alongside organizing various seminars. The company's corporate headquarters are situated in Fribourg, Switzerland, and it operates as a subsidiary of M.R.S.I. Medical Research, Services and Investments S.A.

Company Valuation

Slightly overvalued
3/7

Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBITDA,

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Somewhat favourable
5/7

The average target price of AEVS.SW is 17.0 and suggests 32.8% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to i

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

28.08.2026 23:34

"Worsha was seen as a hawk": The market sharply raised expectations for a rate hike in September

28.08.2026 21:40

"The Schrodinger's Cat Situation": Analysts Take Stock of Six Months of the U.S.-Iran War

28.08.2026 20:58

BioNTech and Roche have halted a cancer vaccine trial. What does this mean for the industry?

28.08.2026 19:14

The Fed "has a lot of work ahead" if inflation doesn't come down quickly — Warsh

28.08.2026 19:05

"The Main Focus for the Markets": What to Expect from the Fed Chair's Speech in Jackson Hole

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026